Beactica

27 articles about Beactica

• Beactica Therapeutics announces the selection of BEA-17 as a preclinical candidate

  9/5/2023

  Beactica Therapeutics AB announced the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers.

• Beactica Therapeutics appoints Jarl Ulf Jungnelius M.D. to its Board of Directors as it advances towards clinical-stage activities

  6/19/2023

  Beactica Therapeutics AB, the Swedish precision oncology company, announced the appointment of Jarl Ulf Jungnelius M.D. to its Board of Directors.

• Beactica Therapeutics to present breakthrough in YAP-TEAD programme at the Hippo Pathway Drug Development Summit 2023

  5/16/2023

  Beactica Therapeutics AB, the Swedish precision oncology company, announced that its YAP-TEAD programme has been selected for an oral presentation at the 2nd Hippo Pathway Targeted Drug Development Summit 2023.

• Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

  4/11/2023

  Beactica Therapeutics AB, the Swedish precision oncology company, announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.

• Beactica Therapeutics and Oscotec mutually agree to conclude oncology collaboration

  4/4/2023

  Beactica Therapeutics AB, the Swedish precision oncology company, and Oscotec Inc., the Korean drug development company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.

• Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma

  2/1/2023

  Beactica Therapeutics AB announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma.

• Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration

  9/6/2022

  Dong-A ST Co., Ltd., a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.

• Beactica Therapeutics and University of Dundee announce collaboration to develop WRN inhibitors to target cancer

  1/12/2021

  Beactica Therapeutics AB, the Swedish drug discovery company, and University of Dundee, a top-ranked university in the UK for biological sciences, announced a new research collaboration agreement.

• Beactica Therapeutics Participates in Innovative Training Network on Targeted Protein Degradation

  10/30/2019

  Beactica Therapeutics, the Swedish drug discovery company, announced its participation in a Marie Skłodowska-Curie Innovative Training Network called UbiMotif.

• Beactica Therapeutics Appoints Several High-profile People to Strengthen its Strategic Focus on Drug Discovery

  9/10/2019

  Beactica Therapeutics announced the appointment of a Head of Preclinical Development, two new members of the Board, and a clinical advisor.

• Beactica Wins Grant to Develop Combination Therapy for Glioblastoma

  6/18/2019

  Beactica AB, the Swedish drug discovery company, announced that it has been awarded a grant of 2.8 MSEK from SweLife and Medtech4Health for its project focused on finding effective therapies for glioblastoma, an aggressive form of brain cancer.

• Beactica Secures Another Round of Financing as Novel Glioblastoma Treatment Advances Towards Pre-clinical Development

  6/4/2019

  Beactica AB, the Swedish drug discovery company, announced the completion of a new financing round that will enable the company to take its leading pipeline programme in oncology to the next stage.

• Dong-A ST and Beactica Expand Their Research and Licence Agreement to Develop New Cancer Treatments

  3/12/2019

  Dong-A ST Co., Ltd., the Korean pharmaceutical company, and Beactica AB, the Swedish drug discovery company, announced an expansion of their research and licensing agreement.

• Beactica Closes Financing Round to Accelerate its Pipeline of Novel Cancer Therapeutics

  8/28/2018

  Beactica today announced the completion of its latest financing round, providing significant funds that will be used to advance the Company's internal pipeline of discovery-stage oncology programmes.

• Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market

  6/27/2018

  Symcel – has announced the appointment of two new highly experienced board members; Erik Walldén and Stefan Löfås.

• Beactica Announces Glioblastoma Research Collaboration With Uppsala Universitet And The DDD Platform At SciLifeLab

  5/16/2017

• Dong-A ST And Beactica Announce Licence And Collaboration Agreement To Develop New Cancer Treatments

  10/26/2016

• Beactica Scientists Publish Strategies For Discovery Of Allosteric Modulators

  5/27/2015

• Beactica Scientists Publish Strategies For Discovery Of Allosteric Modulators

  5/26/2015

• Beactica Closes Financing Round Successfully To Progress Epigenetic Drug Discovery Programmes

  12/15/2014